Scientists mine drugs database for new diabetes treatment

Feb 22, 2009
Scientists mine drugs database for new diabetes treatment
A natural compound (left) and related molecule (right) that was identified using a new drug discovery method and could lead to a new class of drugs to treat type 2 diabetes.

(PhysOrg.com) -- Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process. This finding could spark a completely new class of drugs to treat type 2 diabetes.

In work published today (22 February) in Nature Chemical Biology researchers at the University of Oxford explain how they have exploited new technology to create a cheap and efficient method of drug discovery that will allow small academic labs to search a large database of drugs to find treatments for diabetes and many other diseases. They have used this new method to identify a small molecule which they are using to understand how insulin is secreted in response to increases in blood sugar.

Lead researcher Dr Grant Churchill said: "A lot of diseases are caused by problems with important proteins within cells. We need to find small molecules that change the function of these proteins both to discover how they work and in addition because these small molecules may also work as treatments for disease. The approach we have developed allows us to do this much more quickly and cheaply than many of the current methods. Ultimately this will speed up the process of getting better treatments into the clinic for patients."

Starting with a natural chemical and systematically modifying its chemical structure is a proven technique and common drugs such as beta-blockers and anti-histamines were discovered this way. However, these discoveries involved lengthy chemical syntheses starting with the natural chemical (adrenalin and histamine respectively).

"Our method also begins with the natural chemical but rather than modifying it with a time-consuming and expensive chemical syntheses conducted by a team of chemists, ours uses computers to identify corresponding small molecules for research and medicine. The major difference is that we have linked the computational methods commonly used by pharmaceutical companies to a freely available database of 5 million existing compounds - the ZINC database. This means we cut out a hugely time consuming and financially intensive part of the process, which is difficult for small academic labs to do," Churchill said.

The team has tested their method by successfully identifying a small molecule called Ned-19. This molecule was found after information about the natural chemical NAADP was entered into the computer system and cross referenced with the ZINC database. In collaboration with scientists at the University of Southampton, led by A.Ganesan, Ned-19 was prepared on a larger scale and separated. Further experiments were carried out with these compounds to confirm the activity of Ned-19. Using Ned-19 in experiments they have discovered that NAADP plays a crucial role in insulin secretion and therefore represents a brand new target for diabetes drugs.

Churchill continued: "Unfortunately, asking someone to take Ned-19 would actually give them diabetes! But now that we know how important NAADP is we can start to look for drugs that work with NAADP to increase insulin secretion rather than decrease it. In fact, we have colleagues who are already working on this using our tool."

Professor Douglas Kell, BBSRC Chief Executive said: "This is great news for our community of researchers and will provide a powerful tool for research in the future. This discovery about insulin secretion shows how important it is to have centrally held data repositories that are free to access. Such sharing of data and information can have really significant impact, right across the board."

More information: Nature Chemical Biology: doi: 10.1038/nchembio.150

Source: Biotechnology and Biological Sciences Research Council

Explore further: Geneticists solve 40-year-old dilemma to explain why duplicate genes remain in the genome

add to favorites email to friend print save as pdf

Related Stories

New form of insulin can be inhaled rather than injected

Mar 23, 2010

Scientists today described a new ultra-rapid acting mealtime insulin (AFREZZA™) that is orally inhaled for absorption via the lung. Because the insulin is absorbed so rapidly, AFREZZA's profile closely ...

Tailor-made recombinant proteins in mammals

Feb 09, 2009

A new way to direct chemical modifications to specific sites on recombinant proteins - including the monoclonal antibodies so important in the pharmaceutical industry - has been developed by Carolyn Bertozzi ...

Scientists develop a new strategy to fight obesity

Oct 27, 2008

The antibody works against the gastric hormone ghrelin (pronounced "grell-in"), which has been linked to weight gain and fat storage through its metabolic actions. These findings point towards a potentially novel treatment ...

Single Molecule Makes Obese Mice Healthy

Nov 01, 2006

Researchers have used a single compound to increase the lifespan of obese mice, and found that the drug reversed nearly all of the changes in gene expression patterns found in mice on high calorie diets—some ...

Recommended for you

World's first microbe 'zoo' opens in Amsterdam

10 hours ago

The world's first "interactive microbe zoo" opened in Amsterdam on Tuesday, shining new light on the tiny creatures that make up two-thirds of all living matter and are vital for our planet's future.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Avitar
not rated yet Feb 23, 2009
For god sakes! What will it take to cut out the treatment BS? The there was a tentative cure from animal studies published in Cell in Dec. 2007, the gastro-intestinal by-pass accidental cures point the way cause and cure. The math of diabetes has always pointed to an introduced substance being the responsible agent for the type II diabetes epidemic. Thanks to the gastro-intestinal operations, curing diabetes we can now assume that it is one of the synthetic fats, like margarine that were introduced into the diets in the twentieth century. We should identify which fat or fats by the end of the year and have removal of that fat before the end of 2010 and a complete cure by the end of that year. Of course, with the FDA complete lack of concern for the health of the American people the cure would not be generally available for years after that. Are we going to have to arrest the company MBAs before they allow a cure?
I have heard the old MBA jokes about how irresponsible and careless the march of dimes was, they lost their disease. However, spending money on a treatment is not a responsible use of money at this point.